LIA
ABBV icon

Limestone Investment Advisors’s AbbVie ABBV Stock Holding History

Limestone Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Buy
3,200
+200
+7% +$43K 0.06% 228
2026
Q1 		$652K Buy
3,000
+2,200
+275% +$488K 0.05% 189
2025
Q4 		$183K Buy
+800
New +$182K 0.02% 347
2025
Q3 		– Sell
-12,200
Closed -$2.26M – 526
2025
Q2 		$2.26M Buy
+12,200
New +$2.27M 0.2% 107

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Limestone Investment Advisors's ABBV Position: Q2 2026 in Review

Limestone Investment Advisors sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,340 shares — an estimated $288K sold.

Limestone Investment Advisors first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $291K in Q1 2026. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Limestone Investment Advisors reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Limestone Investment Advisors sold 1,340 AbbVie shares in Q2 2026, an estimated $288K.
  • Limestone Investment Advisors first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
  • Limestone Investment Advisors's AbbVie position peaked at $291K in Q1 2026.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Limestone Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.